IP Library › Granted Patent US 10,393,753
Granted Patent B2
US 10,393,753 · App. 15/455,873 · Granted Aug 27, 2019

Human exhaled aerosol droplet biomarker system and method

Inventors: Donald K. Milton (University Park, MD); Ian M. White (Ellicott City, MD)
Assignee: University of Maryland, College Park
G01N33/6863C12Q1/6804C12Q1/6853G01N33/5308G01N33/54366G01N2333/52G01N2333/525G01N2333/545G01N2333/5418G01N2333/5421G01N2333/5437G01N2333/57G01N2800/122G01N2800/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,393,753
App. No.
15/455,873
Granted
Aug 27, 2019
Kind
B2
Abstract

A system and method for detecting a biomarker in exhaled breath condensate nanodroplets comprises noninvasively collecting exhaled breath condensate nanodroplets of a subject, and analyzing said nanodroplets utilizing immuno-quantitative polymerase chain reaction to detect one or more target biomarkers.

Claims (14)

1. A method for detecting a biomarker in exhaled breath condensate nanodroplets, comprising the steps of:

noninvasively collecting exhaled breath condensate (EBC) nanodroplets from a subject by impacting said nanodroplets into a liquid medium; and

analyzing said nanodroplets utilizing immuno-quantitative polymerase chain reaction (IqPCR) to detect one or more target biomarkers in said nanodroplets.

2. The method of claim 1 , wherein at least one of said target biomarkers is associated with a respiratory disease, disorder or infection.

3. The method of claim 2 , wherein said respiratory disease, disorder or infection is selected from the group consisting of lung cancer, asthma, chronic obstructive pulmonary disease, tuberculosis, influenza, a human immunodeficiency virus (HIV) related infection, and an acquired immune deficiency syndrome (AIDS) related infection.

4. The method of claim 1 , wherein said biomarkers comprise cytokines.

5. The method of claim 4 , wherein said cytokines are selected from the group consisting of IFN-gamma, IL-1 beta, IL-7, IL-8, IL-13, and TNF-alpha.

6. The method of claim 1 , comprising the further step of determining a volume of said nanodroplets generated by the subject, and standardizing a concentration of said detected biomarkers within said collected nanodroplets.

7. The method of claim 1 , wherein the subject is disposed in a supine position during said collecting step.

8. The method of claim 1 , comprising the further step of providing a collection device configured for collecting said nanodroplets, said collection device configured to determine the number and size distribution of said nanodroplets.

9. The method of claim 8 , wherein said collection device comprises an optical particle counter.

10. The method of claim 1 , wherein said IqPCR assay comprises a microbead having an antibody immobilized thereon, wherein said antibody binds to a particular one of said target biomarkers.

11. The method of claim 10 , wherein said IqPCR exhibits at least a 10-fold increase in sensitivity in detection of said target biomarkers as compared to enzyme-linked immuno-sorbent assay (ELISA).

12. The method of claim 11 , wherein said IqPCR exhibits at least a 1000-fold increase in sensitivity in detection of said target biomarkers as compared to enzyme-linked immuno-sorbent assay (ELISA).

Continuity (4)
Division 14017764 · Sep 4, 2013
Provisional Application 61726423 · Nov 14, 2012
Provisional Application 61696641 · Sep 4, 2012
Related Publication 20170184609A1 · Jun 29, 2017
Cited By (4)
US 12,369,816 US 12,442,726 US 12,533,047 US 12,676,232